Gabapentinoid | Moderate Risk

Gabapentin (Neurontin)

Gabapentin risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Neurontin, Nupentin 300, Gabapentin Sandoz, Gabacor, GAPENTIN and 8 more.

Source: PBS, TGA Updated April 2026

Gabapentin (brand names: Neurontin, Nupentin 300, Gabapentin Sandoz, Gabacor, GAPENTIN and 8 more) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Gabapentinoid with CNS depression risk and potential for abuse when combined with opioids.

Key Takeaways

  • TGA Schedule: S4 in Australia
  • Risk level: Moderate (3 points)
  • CNS depressant: May cause sedation, impair driving, and affect work capacity
  • Respiratory depression risk: Requires monitoring, especially with other CNS depressants
  • Recommended maximum duration: 90 days
  • PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S4 PBS listed

Risk Profile

Risk Level Moderate
Risk Points 3
CNS Depressant Yes
Respiratory Risk Yes
Max Duration 90 days

Gabapentinoid with CNS depression risk and potential for abuse when combined with opioids.

Regulatory and Compliance Guidance

When Gabapentin appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.

Work capacity impact: As a CNS depressant, Gabapentin may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.

Australia TGA / PBS / State Schemes

Classified as S4 under the Therapeutic Goods Administration (TGA).

Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.

United Kingdom NICE / MHRA / FPM

NICE CG173 (Neuropathic Pain) includes pregabalin and gabapentin as treatment options for neuropathic pain. The MHRA has issued safety warnings about gabapentinoid misuse and respiratory depression risk when combined with opioids.

UK drug driving laws (Section 5A Road Traffic Act 2006) set specific limits for prescription drugs that cause impairment. Employers and occupational health advisors should assess fitness to work.

Need to assess this medication across your caseload?

Run a full risk assessment including Gabapentin interactions and compliance checks.

AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.

Book a Demo

Free trial available. No credit card required.

Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.